LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

Search

BioCryst Pharmaceuticals Inc

Closed

SectorHealthcare

8.38 1.33

Overview

Share price change

24h

Current

Min

8.2

Max

8.38

Key metrics

By Trading Economics

Income

5.1M

5.1M

Sales

18M

163M

Profit margin

3.113

Employees

580

EBITDA

-84M

-62M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+101.91% upside

Dividends

By Dow Jones

Next Earnings

3 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-73M

1.8B

Previous open

7.05

Previous close

8.38

News Sentiment

By Acuity

50%

50%

182 / 373 Healthcare

BioCryst Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

19 Aug 2025, 23:25 UTC

Earnings
Major Market Movers

James Hardie Industries Falls as 1Q Earnings Misses Analyst Estimates

19 Aug 2025, 22:23 UTC

Earnings

Transurban Signals Faster Distribution Growth in Fiscal Year 2026

19 Aug 2025, 23:57 UTC

Acquisitions, Mergers, Takeovers

Regis Resources: Remark Follows Media Report About Potential Acquisition of Remaining Tropicana Stake

19 Aug 2025, 23:57 UTC

Acquisitions, Mergers, Takeovers

Regis Resources: Not in Advanced Discussions on Any Specific M&A Opportunity

19 Aug 2025, 23:42 UTC

Market Talk

Gold Consolidates Amid Russia-Ukraine Peace Deal Worry, Dovish Fed Hopes -- Market Talk

19 Aug 2025, 23:39 UTC

Market Talk

Nikkei May Decline on Profit-Taking Amid Tariff Uncertainty -- Market Talk

19 Aug 2025, 22:39 UTC

Market Talk

APA's Result, Guidance Unlikely to Shift Share Price Much -- Market Talk

19 Aug 2025, 22:08 UTC

Earnings

Transurban Signals Faster Distribution Growth in FY 2026

19 Aug 2025, 22:06 UTC

Earnings

ZTO Express (Cayman) Announces Interim Div of 30c/ADS

19 Aug 2025, 22:04 UTC

Earnings

ZTO Express (Cayman) 2Q Rev $1.65B >ZTO

19 Aug 2025, 22:03 UTC

Earnings

Transurban Expects Distribution of A$0.69/Share in FY 2026

19 Aug 2025, 22:03 UTC

Earnings

Transurban FY Proportional Free Cash A$2.66 Billion, Up 6.2%

19 Aug 2025, 22:03 UTC

Earnings

Transurban FY Proportional Operating Ebitda A$2.85 Billion, Up 7.4%

19 Aug 2025, 22:02 UTC

Earnings

Transurban FY Proportional Ebitda A$2.68 Billion, Up 1.0%

19 Aug 2025, 22:02 UTC

Earnings

ZTO Express (Cayman) 2Q Adjusted Net 35c/ADS

19 Aug 2025, 22:02 UTC

Earnings

ZTO Express (Cayman) 2Q Net 33c/ADS

19 Aug 2025, 22:02 UTC

Earnings

Transurban FY Proportional Toll Revenue A$3.73 Billion, Up 5.6%

19 Aug 2025, 22:02 UTC

Earnings

Transurban FY Revenue A$3.77 Billion, Down 8.5%

19 Aug 2025, 22:01 UTC

Earnings

Transurban FY Net Profit A$133 Million, Down 59%

19 Aug 2025, 21:01 UTC

Earnings

James Hardie Industries: Presently, Demand in Both Repair and Remodel and New Construction in N Amer Is Challenging >JHX

19 Aug 2025, 21:00 UTC

Earnings

James Hardie Industries 1Q EPS 15c >JHX

19 Aug 2025, 21:00 UTC

Earnings

James Hardie Industries 1Q Sales $899.9M >JHX

19 Aug 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

19 Aug 2025, 20:48 UTC

Earnings

Spark New Zealand Ltd.: Past Year Has Been One of the Most Challenging Periods in Co's History

19 Aug 2025, 20:47 UTC

Earnings

Spark New Zealand Ltd. FY25 Net NZD252M

19 Aug 2025, 20:47 UTC

Earnings

Spark New Zealand Ltd. FY25 Rev NZD3.725B

19 Aug 2025, 20:35 UTC

Earnings

Caterpillar Stock Rises. Wall Street Is Getting More Enthusiastic About Recovery. -- Barrons.com

19 Aug 2025, 20:33 UTC

Earnings
Acquisitions, Mergers, Takeovers

These Stocks Moved the Most Today: Intel, Home Depot, Palo Alto, Viking Therapeutics, Palantir, Medtronic, and More -- Barrons.com

19 Aug 2025, 20:32 UTC

Earnings
Acquisitions, Mergers, Takeovers

Alcon Cuts 2025 View To Sales $10.3B-$10.4B >ALC.EB

19 Aug 2025, 20:31 UTC

Earnings
Acquisitions, Mergers, Takeovers

Alcon 2Q EPS 35c >ALC.EB

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

101.91% upside

12 Months Forecast

Average 16.92 USD  101.91%

High 30 USD

Low 8.5 USD

Based on 6 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

5

Buy

1

Hold

0

Sell

Sentiment

By Acuity

182 / 373 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.